BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17679700)

  • 1. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.
    Diamond GA; Bax L; Kaul S
    Ann Intern Med; 2007 Oct; 147(8):578-81. PubMed ID: 17679700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone: a thunderstorm from scarce and fragile data.
    Mulrow CD; Cornell J; Localio AR
    Ann Intern Med; 2007 Oct; 147(8):585-7. PubMed ID: 17938398
    [No Abstract]   [Full Text] [Related]  

  • 4. Rosiglitazone and cardiovascular risk.
    Kaul S; Diamond GA
    Curr Atheroscler Rep; 2008 Oct; 10(5):398-404. PubMed ID: 18706281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The record on rosiglitazone and the risk of myocardial infarction.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
    [No Abstract]   [Full Text] [Related]  

  • 6. Rosiglitazone and cardiovascular risk.
    Diamond GA; Kaul S
    N Engl J Med; 2007 Aug; 357(9):938-9; author reply 939-40. PubMed ID: 17806135
    [No Abstract]   [Full Text] [Related]  

  • 7. Rosiglitazone and cardiovascular risk.
    Mannucci E; Monami M; Marchionni N
    N Engl J Med; 2007 Aug; 357(9):938; author reply 939-40. PubMed ID: 17806136
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.
    Nissen SE; Wolski K
    N Engl J Med; 2007 Jun; 356(24):2457-71. PubMed ID: 17517853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspective: effect of rosiglitazone on cardiovascular outcomes.
    Nissen SE
    Curr Cardiol Rep; 2007 Sep; 9(5):343-4. PubMed ID: 17877927
    [No Abstract]   [Full Text] [Related]  

  • 10. Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?
    Stone JC; Furuya-Kanamori L; Barendregt JJ; Doi SA
    Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):223-7. PubMed ID: 25515780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone and cardiovascular risk.
    Bracken MB
    N Engl J Med; 2007 Aug; 357(9):937-8; author reply 939-40. PubMed ID: 17761600
    [No Abstract]   [Full Text] [Related]  

  • 12. Rosiglitazone and cardiovascular risk.
    Psaty BM; Furberg CD
    N Engl J Med; 2007 Jun; 356(24):2522-4. PubMed ID: 17517854
    [No Abstract]   [Full Text] [Related]  

  • 13. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.
    Home PD; Pocock SJ; Beck-Nielsen H; Gomis R; Hanefeld M; Jones NP; Komajda M; McMurray JJ;
    N Engl J Med; 2007 Jul; 357(1):28-38. PubMed ID: 17551159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.
    Singh S; Loke YK; Furberg CD
    JAMA; 2007 Sep; 298(10):1189-95. PubMed ID: 17848653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
    Marx N
    Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.
    Boyle P
    South Med J; 2007 Nov; 100(11):1063-4. PubMed ID: 17984728
    [No Abstract]   [Full Text] [Related]  

  • 18. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.
    Wallach JD; Wang K; Zhang AD; Cheng D; Grossetta Nardini HK; Lin H; Bracken MB; Desai M; Krumholz HM; Ross JS
    BMJ; 2020 Feb; 368():l7078. PubMed ID: 32024657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective.
    McGuire DK
    Diab Vasc Dis Res; 2007 Jun; 4(2):77-9. PubMed ID: 17654438
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.
    Loke YK; Kwok CS; Singh S
    BMJ; 2011 Mar; 342():d1309. PubMed ID: 21415101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.